Pamela Becker, MD, PhD
Dr. Pamela Becker is a board-certified UCI Health hematologist who specializes in the treatment of hematologic malignancies, in particular,
IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
Dr. Pamela Becker is a board-certified UCI Health hematologist who specializes in the treatment of hematologic malignancies, in particular,
Dr. Luskin received her MD from the University of Pennsylvania Perelman School of Medicine in 2009. She completed residency training in Internal Medicine at Brigham and Women's Hospital, followed by a fellowship in Hematology and Oncology at the University of Pennsylvania. She joined Dana-Farber as a member of the Adult Leukemia program in 2016.
Melhem Solh, M.D., is board certified in the subspecialties of medical oncology and hematology. Dr. Solh is a Northside Hospital Blood and Marrow Transplant and Leukemia Program physician.In 2019, Dr. Solh was recognized as among Atlanta’s Top Doctors in his specialty by Castle Connolly.
Saurabh Chhabra, MD, received his Medical Degree from the University of Delhi in 2002. He completed his Internal Medicine Residency at Rutgers-Robert Wood Johnson Medical School in New Brunswick, NJ in 2008. He then went on to complete his Fellowship in Hematology/Oncology at Cancer Institute of New Jersey in 2011. Dr. Chhabra then moved to Stanford University, Stanford, CA and completed his Fellowship in Blood and Marrow Transplantation in 2012.
Dr. Timothy Pardee specializes in hematology and oncology with Wake Forest Baptist Health in Winston-Salem, North Carolina. He is also the director of Leukemia Translational Research.
Dr. Michael Burke is an Associate Professor at the Children’s Hospital of Wisconsin (CHW) in the Division of Hematology/Oncology/Blood & Marrow Transplantation. He is Director of the Pediatric Leukemia & Lymphoma Program at CHW and Co-Director of the Developmental Therapeutics Program where he oversees all early phase clinical trials (Phase I and II studies) at CHW.
A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 36 eligible subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN), including Chronic Myelomonocytic Leukemia (CMML), and 36 eligible subjects with